{"nctId":"NCT01765764","briefTitle":"Bimatoprost for the Treatment of Eyebrow Hypotrichosis","startDateStruct":{"date":"2013-03-13","type":"ACTUAL"},"conditions":["Eyebrow Hypotrichosis"],"count":357,"armGroups":[{"label":"Bimatoprost Solution BID","type":"EXPERIMENTAL","interventionNames":["Drug: bimatoprost solution"]},{"label":"Bimatoprost Solution QD","type":"EXPERIMENTAL","interventionNames":["Drug: bimatoprost solution","Drug: Vehicle to bimatoprost solution"]},{"label":"Vehicle to Bimatoprost Solution BID","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Vehicle to bimatoprost solution"]}],"interventions":[{"name":"bimatoprost solution","otherNames":[]},{"name":"Vehicle to bimatoprost solution","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n-Adult participants with eyebrow hypotrichosis (inadequate eyebrow growth).\n\nExclusion Criteria:\n\n* Patients with disease, infection, or abnormality of the eyebrow area\n* Patients with permanent eyebrow loss due to over-grooming","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With at Least a 1-Grade Increase (Improvement) in the 4-Point Global Eyebrow Assessment (GEBA) Scale","description":"The physician evaluated eyebrow fullness using the 4-point GEBA Scale where: 1=very sparse, 2=sparse, 3=full and 4=very full. The percentage of participants with at least a 1-grade increase from Baseline is reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"83.9","spread":null},{"groupId":"OG001","value":"77.1","spread":null},{"groupId":"OG002","value":"43.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Eyebrow Fullness as Measured Using Digital Monitoring System Image Analysis (DMSIA)","description":"Photographs were taken of the eyebrows. Eyebrow fullness was measured by DMSIA for both eyes and averaged. Eyebrow fullness was reported in millimeters squared (mm\\^2). A positive change from Baseline indicated fuller eyebrows (improvement).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"101.08","spread":"47.252"},{"groupId":"OG001","value":"97.80","spread":"41.525"},{"groupId":"OG002","value":"98.17","spread":"49.657"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34.51","spread":"35.940"},{"groupId":"OG001","value":"30.96","spread":"33.638"},{"groupId":"OG002","value":"6.42","spread":"26.870"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Eyebrow Darkness as Measured Using DMSIA","description":"Photographs were taken of the eyebrows. Eyebrow darkness (intensity) was measured by DMSIA for both eyes and averaged. Eyebrow darkness was reported in intensity units. A negative change from Baseline indicated darker eyebrows (improvement).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.90","spread":"6.314"},{"groupId":"OG001","value":"53.59","spread":"7.688"},{"groupId":"OG002","value":"52.87","spread":"6.985"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.53","spread":"3.294"},{"groupId":"OG001","value":"-3.76","spread":"3.212"},{"groupId":"OG002","value":"0.11","spread":"1.837"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With 'Very Satisfied' or 'Mostly Satisfied' in Eyebrow Satisfaction Scale (ESS) Item #6","description":"ESS Item #6 measured the participant's satisfaction with eyebrow treatment: \"Overall, how satisfied are you with the way the eyebrow treatment makes your eyebrows look right now?\" using a 5-point scale where: 1=very satisfied, 2=mostly satisfied, 3=neither dissatisfied nor satisfied, 4=mostly dissatisfied and 5=very dissatisfied. The percentage of participants 'very satisfied' or 'mostly satisfied' is reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.3","spread":null},{"groupId":"OG001","value":"52.5","spread":null},{"groupId":"OG002","value":"36.4","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":118},"commonTop":["Upper respiratory tract infection"]}}}